MJ
Therapeutic Areas
Larimar Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CTI-1601 (Nomaxofusp) | Friedreich's Ataxia | Phase 2 |
| CTI-1601 | Friedreich's Ataxia | Phase 1 |
Leadership Team at Larimar Therapeutics
CB
Carole Ben-Maimon, M.D.
President, Chief Executive Officer, and Director
MR
Michael R. Celano
Chief Financial Officer
JC
John C. McKew, Ph.D.
Chief Scientific Officer
NJ
Nancy J. Rusinko, Ph.D.
Chief Development Officer and Director
RG
Russell G. Clayton, D.O.
Chief Medical Officer
PG
Peter G. Tombros
Chairman of the Board
AI
Andrew I. Sassine, J.D.
Director
DB
David B. Stevens, Ph.D.
Director